WhaleWatch

DATE2 Sept

NIFTY 23,914 ▼ 0.59%BANK NIFTY 57,172 ▼ 0.41%NIFTY IT 31,103 ▼ 1.25%NIFTY PHARMA 26,781 ▼ 0.04%IFCI 98 ▲ 12.67%RRKABEL 2,630 ▼ 8.34%NIACL 199 ▲ 7.18%AEGISVOPAK 286 ▲ 6.00%AIIL 507 ▼ 5.91%HEROMOTOCO 5,300 ▼ 4.59%FINCABLES 1,191 ▼ 4.57%SAILIFE 1,587 ▲ 4.54%VOLTAS 1,152 ▼ 4.39%HFCL 226 ▼ 4.38%NIFTY 23,914 ▼ 0.59%BANK NIFTY 57,172 ▼ 0.41%NIFTY IT 31,103 ▼ 1.25%NIFTY PHARMA 26,781 ▼ 0.04%IFCI 98 ▲ 12.67%RRKABEL 2,630 ▼ 8.34%NIACL 199 ▲ 7.18%AEGISVOPAK 286 ▲ 6.00%AIIL 507 ▼ 5.91%HEROMOTOCO 5,300 ▼ 4.59%FINCABLES 1,191 ▼ 4.57%SAILIFE 1,587 ▲ 4.54%VOLTAS 1,152 ▼ 4.39%HFCL 226 ▼ 4.38%

Morning brief · Friday, 4 September 2026

Blue Jet Healthcare slide sparks debate over glitch or structural reset

Market pulse

The Nifty fell 0.59 percent to close at 23,914 while Bank Nifty was flat. Under the hood, IFCI surged 12.67 percent, while R R Kabel shed 8.34 percent.

From the investor's mind

One post worth your time, explained

@aditya_kondawar · on X

An analysis shared by Aditya Kondawar highlights that the global artificial intelligence services opportunity could scale to between US$ 300 billion and US$ 400 billion by 2030. This projected growth is anchored by a structured demand landscape, as emphasized by the Infosys chief financial officer during a meeting with brokerage Nomura. To capture this medium- to long-term demand, the company is focusing on six specialized AI value pools. The first of these strategic segments is AI strategy and engineering, which specifically incorporates agentic technology.

Know more about the stock

Word in the street

What the wider market is buzzing about

Blue Jet Healthcare Limited

₹580Past year ▼ 18%M.cap ₹10,962 Cr

Investors are closely studying Blue Jet Healthcare Limited after its stock fell 17.61 percent over the past year, bringing its market cap to about 10,962 crore. To understand the company better, shareholders are sharing an analytical piece by Manthan Rastogi that questions whether the slide represents a temporary glitch or a structural reset for its regulated market operations. Crucially, the community is trying to map the Bempedoic Acid value chain. They are discussing how value is captured among Neuland, Bluejet, and Morepen, specifically comparing the innovator channel of Esperion and Daiichi Sankyo against alternative generic pathways.

Know more about the stock

Yesterday's big moves